TAMPA, Fla. — Moffitt Most cancers Heart has handled its first affected person in an investigator-initiated, section 1 medical trial investigating the security and efficacy of a chimeric antigen receptor T-cell (CAR T) remedy for prostate most cancers that has metastasized to the bone. Roughly 90% of males with superior prostate most cancers will develop bone metastases. The illness considerably impacts sufferers, inflicting excessive bone ache.
The CAR T-cell remedy, developed within the lab of Moffitt immunologist Daniel Abate-Daga, PhD, makes use of gamma delta T cells to focus on a tumor biomarker extremely expressed in bone metastatic prostate most cancers referred to as prostate stem cell antigen. Whereas many CAR T therapies make use of alpha beta T cells, gamma delta T cells, which characterize lower than 5% of all T cells within the physique, have distinctive organic properties that enable them to acknowledge a broader vary of antigens by way of their T cell receptor, together with molecules sometimes related to burdened or contaminated cells, similar to most cancers. Most significantly, gamma delta T cells are distinctive in that they’re most effective when mixed with a drug (zoledronate) that’s generally used to guard the bone in sufferers with bone metastatic most cancers.
In preclinical research, Abate-Daga’s lab confirmed that the gamma delta CAR T cells considerably decreased the dimensions of tumors and improved survival with restricted toxicity. Moreover, pretreatment with zoledronate, a drugs that helps strengthen bones, activated the CAR T cells by way of a CAR-independent mechanism, permitting for elevated potential to acknowledge and destroy tumors. Along with eliminating tumors, the remedy additionally preserves the well being of the bones, as reported final 12 months in a joint publication with the Conor Lynch, PhD, lab.
“We’re hopeful that this remedy will assist sufferers with prostate most cancers and that this research will probably be simply step one in the direction of the efficient remedy of different bone tumors,” stated Abate-Daga, whose lab developed the remedy in early 2023.
It is a single-center section 1 dose-escalation trial with a 3+3 design. In a 3+3 design, three sufferers are enrolled right into a cohort for a given dose. If no dose-limiting toxicities exist within the cohort, the trial enrolls extra members into the following larger dose cohort. Sufferers with end-stage prostate most cancers with no commonplace of care choices left could be potential candidates for this research.
Jingsong Zhang, MD, PhD, a medical oncologist within the Genitourinary Oncology Division at Moffitt, is the principal investigator for this section 1 trial. Potential members and referring physicians can study extra concerning the trial right here.
Sufferers enrolled within the trial may have their T cells harvested by way of apheresis. The gamma delta T cells will then be engineered in Moffitt’s cell therapies core, including the chimeric antigen receptor. The brand new CAR T cell will then be expanded to the tons of of hundreds of thousands. Earlier than infusion, sufferers will obtain lymphodepletion chemotherapy to make room for the brand new cells. The method from cell assortment to infusion will common 14 days.
About Moffitt Most cancers Heart
Moffitt is devoted to at least one lifesaving mission: to contribute to the prevention and treatment of most cancers. The Tampa-based facility is one in every of solely 56 Nationwide Most cancers Institute-designated Complete Most cancers Facilities, a distinction that acknowledges Moffitt’s scientific excellence, multidisciplinary analysis, and sturdy coaching and training. Moffitt’s knowledgeable nursing workers is acknowledged by the American Nurses Credentialing Heart with Magnet® standing, its highest distinction. For extra info, name 1-888-MOFFITT (1-888-663-3488), go to MOFFITT.org, and comply with the momentum on Fb, Twitter, Instagram and YouTube.
###
